Wijesinghe Namal, Thompson Paul I, McAlister Hugh
Waikato Hospital, Cardiology Department, Private Bag 3200, Hamilton 2001, New Zealand.
Heart Lung Circ. 2006 Oct;15(5):337-9. doi: 10.1016/j.hlc.2006.03.010. Epub 2006 May 12.
Capecitabine, a new member of the fluoropyrimidine family, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumour. Although the cardiotoxicity of 5-FU is well documented, there is little published data about cardiovascular adverse effects of Capecitabine. This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.
卡培他滨是氟嘧啶家族的新成员，是一种口服给药的药物，可将氟尿嘧啶（5-FU）选择性地输送至肿瘤部位。尽管5-FU的心脏毒性已有充分记录，但关于卡培他滨心血管不良反应的公开数据很少。本病例突出了急性冠状动脉综合征作为卡培他滨治疗副作用的可能发展情况。
